Breaking News

Horizon Discovery Wins Drug Screening Contract

Will perform drug combination screening on lead oncology asset

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Horizon Discovery Group’s CombinatoRx division has entered an agreement with a top ten pharma company to profile a lead oncology asset. Horizon CombinatoRx will receive approximately $450,000 for work to be completed within a six-month period.      Horizon will support proof-of-concept, monotherapy screening, and combination screening for the lead asset, providing access to its cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary dru...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters